

Kingsley Hampton

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4833359/kingsley-hampton-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

7

papers

71

citations

4

h-index

8

g-index

9

ext. papers

79

ext. citations

3

avg, IF

1.33

L-index

#	Paper	IF	Citations
7	Novel, human cell line-derived recombinant factor VIII (human-cl rhFVIII; Nuwiiq) in adults with severe haemophilia A: efficacy and safety. <i>Haemophilia</i> , 2016 , 22, 225-231	3.3	30
6	First report on the safety and efficacy of an extended half-life glycoPEGylated recombinant FVIII for major surgery in severe haemophilia A. <i>Haemophilia</i> , 2017 , 23, 689-696	3.3	17
5	Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme. <i>Haemophilia</i> , 2016 , 22, 349-53	3.3	14
4	Turoctocog alfa pegol provides effective management for major and minor surgical procedures in patients across all age groups with severe haemophilia A: Full data set from the pathfinder 3 and 5 phase III trials. <i>Haemophilia</i> , 2020 , 26, 450-458	3.3	6
3	Efficacy and safety of Nuwiiq (human-cl rhFVIII) in patients with severe haemophilia A undergoing surgical procedures. <i>Haemophilia</i> , 2018 , 24, 70-76	3.3	4
2	Illustrative Cases from the Pathfinder Clinical Trials of Patients with Hemophilia A Treated with Turoctocog Alfa Pegol (N8-GP). <i>Patient Preference and Adherence</i> , 2021 , 15, 2443-2454	2.4	
1	Human-Cl Rhfviii Effectively and Safely Prevents Bleeding Episodes in Previously Treated Adult Patients with Severe Haemophilia A. <i>Blood</i> , 2012 , 120, 1132-1132	2.2	